Posttransplant anemia: the role of sirolimus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19553912.
- Also identified by DOI 10.1038/ki.2009.231.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Posttransplant anemia is a common problem that may hinder patients' quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
Medical subject headings
- Anemia
- Kidney Transplantation
- Sirolimus